A new ALK inhibitor overcomes resistance to first‐ and second‐generation inhibitors in NSCLC

Authors:

Abstract
More than 60% of nonsmall cell lung cancer (NSCLC) patients show a positive response to the first ALK inhibitor, crizotinib, which has been used as the standard treatment for newly diagnosed patients with ALK rearrangement. However, most patients inevitably develop crizotinib resistance due to acquired secondary mutations in the ALK kinase domain, such as the gatekeeper mutation L1196M and the most refractory mutation, G1202R. Here, we develop XMU‐MP‐5 as a new‐generation ALK inhibitor to overcome crizotinib resistance mutations, including L1196M and G1202R. XMU‐MP‐5 blocks ALK signaling pathways and inhibits the proliferation of cells harboring either wild‐type or mutant EML4‐ALK in vitro and suppresses tumor growth in xenograft mouse models in vivo . Structural analysis provides insights into the mode of action of XMU‐MP‐5. In addition, XMU‐MP‐5 induces significant regression of lung tumors in two genetically engineered mouse (GEM) models, further demonstrating its pharmacological efficacy and potential for clinical application. These preclinical data support XMU‐MP‐5 as a novel selective ALK inhibitor with high potency and selectivity. XMU‐MP‐5 holds great promise as a new therapeutic against clinically relevant secondary ALK mutations.
Funding Information
  • National Key Research and Development Program of China (2017YFA0504504)
  • National Key Research and Development Program of China (2016YFA0502001)
  • Fundamental Research Funds for the Central Universities (20720190101)
  • Xiamen Municipal Bureau of Science and Technology (3502Z20183006)
  • Project 211 (B06016)
  • National Natural Science Foundation of China (22025702)
  • National Natural Science Foundation of China (91853203)
  • National Natural Science Foundation of China (82021003)
  • National Natural Science Foundation of China (82073874)
  • National Natural Science Foundation of China (81890994)

This publication has 53 references indexed in Scilit: